Lista de obras -

A Braf kinase-inactive mutant induces lung adenocarcinoma.

artículo científico publicado en 2017

A Secondary Mutation in Confers Resistance to RAF Inhibition in a -Mutant Brain Tumor

artículo científico publicado en 2018

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

artículo científico publicado en 2017

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

artículo científico publicado en 2018

B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1.

artículo científico publicado en 2010

Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanism

artículo científico publicado en 2007

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

artículo científico publicado en 2015

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

artículo científico publicado en 2014

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.

artículo científico publicado en 2017

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

artículo científico publicado en 2016

Nucleophosmin/B23 inhibits Eg5-mediated microtubule depolymerization by inactivating its ATPase activity

artículo científico publicado en 2010

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.

artículo científico publicado en 2017

Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53

artículo científico publicado en 2007

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

scientific article published on 17 December 2018

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

artículo científico publicado en 2014

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

scientific article published on 03 June 2019

Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance.

artículo científico publicado en 2013

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

artículo científico publicado en 2010

TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells.

artículo científico publicado en 2017

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

artículo científico publicado en 2017

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

scientific article published on 21 June 2019

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

artículo científico publicado en 2014

Lista de obras de

A Braf kinase-inactive mutant induces lung adenocarcinoma.

A Secondary Mutation in Confers Resistance to RAF Inhibition in a -Mutant Brain Tumor

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1.

Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanism

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

Nucleophosmin/B23 inhibits Eg5-mediated microtubule depolymerization by inactivating its ATPase activity

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.

Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance.

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.